Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes

Virology Journal

Volumn 8, Issue , 2011, Pages

  Guan, Jie ^a   Wen, Bo ^a,b   Deng, Yao ^a   Zhang, Ke ^a   Chen, Hong ^a   Wu, Xiaobing ^a   Ruan, Li ^a   Tan, Wenjie ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMINO ACID; GAMMA INTERFERON; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; HEPATITIS C VACCINE; PROTEIN CE1E2; RECOMBINANT TIAN TAN VACCINIA VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR; DRUG CARRIER; RECOMBINANT VACCINE; VIRUS PROTEIN; VIRUS VACCINE;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; INTRACELLULAR CYTOKINE STAINING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTECTION; SEROTYPE; STAINING; STRUCTURAL GENE; TREATMENT OUTCOME; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; GENE VECTOR; GENETICS; HEPATITIS C; IMMUNOLOGY; METHODOLOGY; MONONUCLEAR CELL; SECRETION; VACCINATION;

ADENOVIRIDAE; HEPATITIS C VIRUS; MUS; VACCINIA VIRUS;

ADENOVIRIDAE; ANIMALS; CROSS PROTECTION; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, SYNTHETIC; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 80155157594     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-506     Document Type: Article

References (39)

1. Flying under the radar: the immunobiology of hepatitis C. Dustin LB, Rice CM, Annu Rev Immunol 2007 25 71 99 10.1146/annurev.immunol.25.022106.141602 17067278 (Pubitemid 46697903)
2. Epidemiology of hepatitis C: geographic differences and temporal trends. Wasley A, Alter MJ, Semin Liver Dis 2000 20 01 1 16 10.1055/s-2000-9506 10895436 (Pubitemid 30421405)
3. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Proc Natl Acad Sci USA 1990 87 6547 6549 10.1073/pnas.87.17.6547 2168552
4. Hepatitis C treatment: current and future perspectives. Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z, Virol J 2010 7 296 10.1186/1743-422X-7-296 21040548
5. Peginterferon and ribavirin treatment for hepatitis C virus infection. Tsubota A, Fujise K, Namiki Y, Tada N, World J Gastroenterol 2011 17 4 419 432 10.3748/wjg.v17.i4.419 21274371
6. Prospects for a vaccine against the hepatitis C virus. Houghton M, Abrignani S, Nature 2005 436 961 966 10.1038/nature04081 16107836 (Pubitemid 41191672)
7. Prophylactic and therapeutic vaccination against hepatitis C virus (HCV): developments and future perspectives. Major ME, Viruses 2009 1 144 165 10.3390/v1020144 21994543
8. Genetic diversity and evolution of hepatitis C virus-15 years on. Simmonds P, J Gen Virol 2004 85 3173 88 10.1099/vir.0.80401-0 15483230 (Pubitemid 39445434)
9. Analysis of a successful immune response against hepatitis C virus. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM, Immunity 1999 10 439 49 10.1016/S1074-7613(00)80044-8 10229187 (Pubitemid 29205480)
10. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV, Proc Natl Acad Sci USA 2002 99 15661 68 10.1073/pnas.202608299 12441397 (Pubitemid 35403988)
11. Immunology of hepatitis B virus and hepatitis C virus infection. Rehermann B, Nascimbeni M, Nat Rev Immunol 2005 5 3 215 29 10.1038/nri1573 15738952 (Pubitemid 40364823)
12. Protective immune response to hepatitis C virus in chimpanzees re-challenged following clearance of primary infection. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, Lanford RE, Hepatology 2001 33 1479 87 10.1053/jhep.2001.24371 11391537 (Pubitemid 32496985)
13. Protection against persistence of hepatitis C. Mehta S, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL, Lancet 2002 359 1478 83 10.1016/S0140-6736(02)08435-0 11988247 (Pubitemid 34457766)
14. Cross-genotype immunity to hepatitis C virus. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, Ray SC, Thomas DL, J Virol 2004 78 1575 81 10.1128/JVI.78.3.1575-1581.2004 14722311 (Pubitemid 38095866)
15. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Major ME, Dahari H, Mihalik K, Puig M, Rice CM, Neumann AU, Feinstone SM, Hepatology 2004 39 1709 20 10.1002/hep.20239 15185313 (Pubitemid 38702673)
16. HCV persistence and immune evasion in the absence of memory T cell help. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM, Science 2003 302 659 662 10.1126/science.1088774 14576438 (Pubitemid 37310924)
17. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM, J Exp Med 2003 197 1645 55 10.1084/jem.20030239 12810686 (Pubitemid 36745340)
18. Hepatitis C vaccines: Inducing and challenging memory T cells. Shiina M, Rehermann B, Hepatology 2006 43 6 1395 8 10.1002/hep.21210 16729320 (Pubitemid 43980119)
19. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Thimme R, Neumann-Haefelin C, Boettler T, Blum HE, Biol Chem 2008 389 5 457 67 10.1515/BC.2008.061 18953713 (Pubitemid 351874195)
20. New insights on adenovirus as vaccine vectors. Lasaro MO, Ertl HC, Mol Ther 2009 17 8 1333 9 10.1038/mt.2009.130 19513019
21. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Thacker EE, Timares L, Matthews QL, Expert Rev Vaccines 2009 8 6 761 77 10.1586/erv.09.29 19485756
22. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Paris RM, Kim JH, Robb ML, Michael NL, Expert Rev Vaccines 2010 9 9 1055 69 10.1586/erv.10.106 20822348
23. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Arribillaga L, de Cerio AL, Sarobe P, Sarobe P, Casares N, Gorriaiz M, Vales A, Bruna-Romero O, Borras-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J, Lasarte JJ, Vaccine 2002 21 3-4 202 10 10.1016/S0264-410X(02)00456-5 12450695 (Pubitemid 35346815)
24. Modulation of vaccine-induced immune responses to hepatitis C virus in Rhesus macaques by altering priming before adenovirus boosting. Rollier C, Verschoor EJ, Paranhos-Baccala G, Drexhage JAR, Verstrepen BE, Berland JL, Himoudi N, Barnfield C, Liljestrom P, Lasarte JJ, Ruiz J, Inchauspe G, Heeney JL, J Infect Dis 2005 192 5 920 929 10.1086/432517 16088843 (Pubitemid 41193091)
25. A T cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, Pwzzanere M, Tafi R, Arcuri M, Fattori E, Lahm A, Luzzago A, Vitelli A, Colloca S, Cortese R, Nicosia A, Nat Med 2006 12 190 197 10.1038/nm1353 16462801 (Pubitemid 43214745)
26. Advances in model systems for hepatitis C virus research. Lanford RE, Bigger C, Virology 2002 293 1 9 10.1006/viro.2001.1316 11853392
27. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ, Proc Natl Acad Sci USA 2003 100 11 6753 8 10.1073/pnas.1131929100 12748380 (Pubitemid 36666652)
28. Construction and application of plasmids containing bidirectional promoters of vaccinia virus. Tsao H, Liu GQ, Ruan L, Chu CM, J Virol 1988 62 4832 4834 2846896 (Pubitemid 19006157)
29. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Elmowalid GA, Qiao M, Jeong SH, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Muethy K, Liang TJ, Proc Natl Acad Sci USA 2007 104 20 8427 32 10.1073/pnas.0702162104 17485666 (Pubitemid 47175504)
30. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Dahari H, Feinstone SM, Major ME, Gastroenterol 2010 139 965 974 10.1053/j.gastro.2010.05.077
31. A vector-based minigene vaccine approach results in strong induction of T cell responses specific of hepatitis C virus. Martin P, Simon B, Lone YC, Chatel L, Barry R, Inchauspe G, Fournillier A, Vaccine 2008 26 20 2471 81 10.1016/j.vaccine.2008.03.028 18423948
32. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes pre-existing anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. Capone S, Meola A, Ercole BB, Vitelli A, Pwzzanera M, Ruggeri L, Davies ME, Tafi R, Santini C, Luzzago A, Fu TM, Bett A, Colloca S, Cortese R, Nicosia A, Folgori A, J Virol 2006 80 4 1688 99 10.1128/JVI.80.4.1688-1699.2006 16439526 (Pubitemid 43228711)
33. A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T cell responses to HCV in BALB/c mice. Deng Y, Zhang K, Tan W, Wang Y, Chen H, Wu X, Ruan L, Vaccine 2009 27 15 2085 8 10.1016/j.vaccine.2009.02.003 19356609
34. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine induced peripheral T helper immune response. Rollier C, Depla E, Drexhage JAR, Verchoor EJ, Verstrepen BE, Fatmi A, Brinster C, Fournillier A, Whelan JA, Whelan M, Jacobs D, Maertens G, Inchauspe G, Heeney JL, J Virol 2004 78 186 196
35. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. Forthal DN, Landucci G, Daar ES, J Virol 2001 75 15 6953 61 10.1128/JVI.75.15.6953-6961.2001 11435575 (Pubitemid 32641582)
36. A genetically humanized mouse model for hepatitis C virus infection. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A, Nature 2011 474 7350 208 11 10.1038/nature10168 21654804
37. Sequence analysis and variation in hepatitis C virus isolate from Hebei Province, China. Bi SL, Bai XH, Cong ME, Liu CB, Chinese Journal of Virology 1993 9 2 114 127
38. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Ng P, R J, Parks DT, Cummings C, Evelegh M, Graham FL, Hum Gene Ther 2000 11 693 699 10.1089/10430340050015590 10757349 (Pubitemid 30180274)
39. Signal peptide replacements enhance expression and secretion of hepatitis C virus envelope glycoproteins. Wen B, Deng Y, Guan J, Yan W, Wang Y, Tan W, Gao J, Acta Biochim Biophys Sin 2011 43 2 96 102 10.1093/abbs/gmq117 21196448